List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development
Merck & Co Inc
Novartis AG
Trellis Bioscience Inc
Vakzine Projekt Magement GmbH
VBI Vaccines Inc
Vical Inc
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles
Bispecific Monoclol Antibody to Target CD3 and Glycoprotein B for Cytomegalovirus (HHV-5) Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSJ-148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CyMVectin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cytomegalovirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPCM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRL-345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBI-1501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBI-1901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPM-2001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Products
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Discontinued Products
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Product Development Milestones
Featured News & Press Releases
Oct 24, 2018: VBI Vaccines to present initial data for VBI-1901 in recurrent glioblastoma (GBM) patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)
Oct 02, 2018: VBI Vaccines late-breaker cytomegalovirus abstract chosen for oral presentation at IDWeek 2018
Sep 25, 2018: VBI Vaccines announces second positive DSMB review in phase 1/2a study of VBI-1901 in recurrent glioblastoma
Sep 25, 2018: VBI Vaccines announces second positive DSMB review in phase 1/2a study of VBI-1901 in recurrent glioblastoma (GBM) patients
May 10, 2018: VBI Vaccines Announces Positive Fil Phase 1 Study Results of Preventative CMV Vaccine
Apr 17, 2018: VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
Jan 17, 2018: VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901
Nov 10, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017
Oct 11, 2017: VBI Vaccines to Present Phase 1 CMV vaccine data at The World Vaccine Congress Europe 2017 in Barcelo
Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit
Aug 15, 2017: VBI Vaccines Announces FDA Acceptance of Investigatiol New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme
Jul 27, 2017: VBI Vaccines Announces Positive Interim Data from Phase 1 Study of Preventative CMV Vaccine
May 02, 2017: VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study
Apr 05, 2017: VBI Vaccines to Present Update on VBI-1901 at the World Vaccine Congress
Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer